RESUMEN
Considering the health relevance of Chagas' disease, recent research efforts have focused on developing more efficient drug delivery systems containing nifurtimox (NFX). This paper comprehensively investigates NFX through conformational analysis and spectroscopic characterization. Using a conformer-rotamer ensemble sampling tool (CREST-xtb), five distinct conformers of NFX were sampled within a 3.0 kcal mol-1 relative energy window. Subsequently, such structures were used as inputs for geometry optimization by density functional theory (DFT) at B3LYP-def2-TZVP level of theory. Notably, harmonic vibrational frequencies were calculated to establish an in-depth comparison with experimental results and existing literature for the NFX or similar molecules and functional groups, thereby achieving a widely reasoned assignment of the mid-infrared band absorptions for the first time. Moreover, UV-VIS spectra of NFX were obtained in several solvents, enabling the determination of the molar absorptivity coefficient for the two electronic transitions observed for NFX. Among the aprotic solvents, a bathochromic effect was observed in the function of the dielectric constants. Furthermore, a hypochromic effect was observed when the drug was dissolved in protic solvents. These findings offer crucial support for new drug delivery systems containing NFX while demonstrating the potential of spectrophotometric studies in establishing quality control assays for NFX drug products.
Asunto(s)
Enfermedad de Chagas , Conformación Molecular , Nifurtimox , Enfermedad de Chagas/tratamiento farmacológico , Nifurtimox/química , Espectrofotometría Ultravioleta , Tripanocidas/química , Modelos Moleculares , Teoría Funcional de la Densidad , Trypanosoma cruzi/efectos de los fármacos , Solventes/químicaRESUMEN
Nifurtimox is a nitroheterocyclic drug employed for treatment of trypanosomiases (Chagas disease and West African sleeping sickness); its use for certain cancers has also been assessed. Despite having been in the market for over 50 years, knowledge of nifurtimox is still fragmentary and incomplete. Relevant aspects of the chemistry and biology of nifurtimox are reviewed to summarize the current knowledge of this drug. These comprise its chemical synthesis and the preparation of some analogues, as well as its chemical degradation. Selected physical data and physicochemical properties are also listed, along with different approaches toward the analytical characterization of the drug, including electrochemical (polarography, cyclic voltammetry), spectroscopic (ultraviolet-visible, nuclear magnetic resonance, electron spin resonance), and single crystal X-ray diffractometry. The array of polarographic, ultraviolet-visible spectroscopic, and chromatographic methods available for the analytical determination of nifurtimox (in bulk drug, pharmaceutical formulations, and biological samples), are also presented and discussed, along with chiral chromatographic and electrophoretic alternatives for the separation of the enantiomers of the drug. Aspects of the drug likeliness of nifurtimox, its classification in the Biopharmaceutical Classification System, and available pharmaceutical formulations are detailed, whereas pharmacological, chemical, and biological aspects of its metabolism and disposition are discussed.
Asunto(s)
Enfermedad de Chagas , Farmacia , Humanos , Nifurtimox/química , Nifurtimox/farmacología , Nifurtimox/uso terapéutico , Enfermedad de Chagas/tratamiento farmacológico , Preparaciones FarmacéuticasRESUMEN
BACKGROUND: Only benznidazole (Bnz) (1) and nifurtimox (Nfx) (2) are licensed for the treatment of Chagas disease although their safety and efficacy profile are far from ideal. Farmanguinhos from Fiocruz has developed seven nitroimidazole compounds (4-10) analogs of megazol (3). OBJECTIVES: To evaluate whether the genotoxic effect of 3 was abolished in the seven nitroimidazoles (4-10) analogs using the in vitro alkaline comet assay (CA) and the in vitro cytokinesis-block micronucleus assay (CBMN) in whole human blood cells (WHBC) and correlate this effect with their trypanocidal activity using bloodstream trypomastigote forms of Trypanosoma cruzi. METHODS: The toxicity of 3-10 to WHBC in the in vitro CA was determined using the fluorescein diacetate/ethidium bromide assay. DNA damage in the in vitro CA was evaluated according to tail size in four classes (0-3) and methyl methane-sulfonate (MMS) was used as a positive control. The cytotoxicity of 3-10 to WHBC in the CBMN was measured using the cytokinesis-block proliferation index and the replication index. The number of the micronucleate cells in 2,000 binucleate cells by experimental group was determined. Mitomycin C and N-deacetyl-N-methylcolchicine were used as positive controls. FINDINGS: Compound 3 showed a significant DNA strand break effect through the in vitro CA and highly significant clastogenic and/or aneugenic effect in the CBMN. Compounds 5, 6, 8, 9 and 10 showed negative results in the CBMN and positive results in the in vitro CA, while the inverse effect was observed for 4 and 7. MAIN CONCLUSIONS: Compound 10 was the most promising to proceed with the development as a drug candidate in the treatment of Chagas disease showing absence of chromosomal cytogenetic damage and high activity against T. cruzi, about two times higher than 3 and the clinical drug 1.
Asunto(s)
Nitroimidazoles/toxicidad , Tripanocidas/toxicidad , Células Sanguíneas/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Ensayo Cometa/métodos , Daño del ADN , Humanos , Pruebas de Micronúcleos/métodos , Nifurtimox/química , Nifurtimox/toxicidad , Nitroimidazoles/química , Valores de Referencia , Reproducibilidad de los Resultados , Tiadiazoles/química , Tiadiazoles/toxicidad , Factores de Tiempo , Tripanocidas/química , Trypanosoma cruzi/efectos de los fármacosRESUMEN
Neglected tropical diseases (NTDs) constitute a group of infectious diseases prevalent in countries with tropical and subtropical climate that affect the poorest individuals and produce high chronic disability associated with serious problems for the health system and socioeconomic development. Chagas disease or American trypanosomiasis is included on the NTDs list. However, even though this disease affects more than 10 million people, mostly in Latin America, causing the death of over 10,000 people every year, only two drugs are approved for its treatment, benznidazole and nifurtimox. These antiparasitic agents were developed almost half a century ago and present several biopharmaceutical disadvantages such as low aqueous solubility and permeability limiting their bioavailability. In addition, both therapeutic agents are available only as tablets and a liquid pediatric formulation is still lacking. Therefore, novel pharmaceutical strategies to optimize the pharmacotherapy of Chagas disease are urgently required. In this regard, nanotechnological approaches may be a crucial alternative for the delivery of both drugs ensuring an effective pharmacotherapy although the successful bench-to-bedside translation remains a major challenge. The present work reviews in detail the formulation and in-vitro/in-vivo analysis of different nanoformulations of nifurtimox and benznidazole in order to enhance their solubility, dissolution, bioavailability and trypanocidal activity.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Nanoestructuras , Nifurtimox/uso terapéutico , Nitroimidazoles/uso terapéutico , Tripanocidas/uso terapéutico , Formas de Dosificación , Humanos , Nifurtimox/administración & dosificación , Nifurtimox/química , Nitroimidazoles/administración & dosificación , Nitroimidazoles/química , Tripanocidas/administración & dosificación , Tripanocidas/químicaRESUMEN
The synthesis and pharmacological evaluation of C1-substituted adamantane hydrazones, their C2-substituted isomers, and C1-substituted adamantane furanoic carboxamides is described. These new adamantane derivatives exhibited an interesting pharmacological profile in terms of trypanocidal activity and selectivity. The most active adduct with the best selectivity in this study was found to be the phenylacetoxy hydrazone 1 b (2-[4-(tricyclo[3.3.1.13,7 ]dec-1-yl)phenyl]-N'-[(5-nitrofuran-2-yl)methylene]acetohydrazide; EC50 =11±0.9â nm, SITb =770).
Asunto(s)
Adamantano/química , Nifurtimox/química , Tripanocidas/síntesis química , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Diseño de Fármacos , Ratas , Relación Estructura-Actividad , Tripanocidas/química , Tripanocidas/farmacología , Trypanosoma brucei brucei/efectos de los fármacos , Trypanosoma cruzi/efectos de los fármacosRESUMEN
OBJECTIVE: This work aims to collect publications of available drugs for reposition and new substance development against the Chagas disease, since they represent the beginning of a path for new discoveries of viable alternatives to improve the prognosis of millions of patients around the world. PATIENTS AND METHODS: An extended research on English and Portuguese-language literature in the Scientific Electronic Library Online - Scielo, SciFinder and PubMed - database was made. The bibliography was screened using the keywords "Chagas Disease" and "Treatment". RESULTS: Despite the low resources available for research and development of drugs against Chagas disease, the knowledge produced in this area is large but not directly proportional to the therapeutic advances. Two categories were analyzed, such as drug repositioning, and new substances were researched. CONCLUSIONS: Even if great findings were reported, more efforts are necessary to find new therapies against Trypanosoma cruzi (T. cruzi).
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Tripanocidas/uso terapéutico , Enfermedad de Chagas/diagnóstico , Reposicionamiento de Medicamentos , Humanos , Estructura Molecular , Nifurtimox/química , Nifurtimox/farmacología , Nifurtimox/uso terapéutico , Nitroimidazoles/química , Nitroimidazoles/farmacología , Nitroimidazoles/uso terapéutico , Pronóstico , Tripanocidas/química , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacosRESUMEN
Chagas disease has spread throughout the world mainly because of the migration of infected individuals. In Brazil, only benznidazole (Bnz) is used; however, it is toxic and not active in the chronic phase, and cases of resistance are described. This work aimed at the synthesis and the trypanocidal evaluation in vitro and in vivo of six new Bnz analogues (3-8). They were designed by exploring the bioisosteric substitution between the amide group contained in Bnz and the 1,2,3-triazole ring. All the compounds were synthesized in good yields. With the exception of compound 7, the in vitro biological evaluation shows that all Bnz analogues were active against the amastigote form, whereas only compounds 3, 4, 5, and 8 were active against trypomastigote. Compounds 4 and 5 showed the most promising activities in vitro against the form of trypomastigote, being more active than Bnz. In vivo evaluation of compounds, 3-8 showed lower potency and higher toxicity than Bnz. Although the 1,2,3-triazole ring has been described in the literature as an amide bioisostere, its substitution here has reduced the activity of the compounds and made them more toxic. Thus, further molecular optimization could provide novel therapeutic agents for Chagas' disease.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Nitroimidazoles/química , Triazoles/química , Tripanocidas/química , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Enfermedad de Chagas/veterinaria , Masculino , Ratones , Nifurtimox/química , Nifurtimox/farmacología , Nifurtimox/uso terapéutico , Nitroimidazoles/farmacología , Nitroimidazoles/uso terapéutico , Tripanocidas/farmacología , Tripanocidas/uso terapéutico , Trypanosoma cruzi/efectos de los fármacosRESUMEN
Chagas disease is caused by the parasite Trypanosoma cruzi and is regularly found among particular people living in Central and South America. Paediatric Chagas disease occurs in 1-10% of infants of infected mothers. The major important point considered in the treatment of congenital Chagas disease focuses on killing the parasite in acute infection and managing signs and symptoms in later stages. Nowadays, two drugs benznidazole and nifurtimox are currently available in the market for the treatment of paediatric Chagas disease.
Asunto(s)
Antiparasitarios/farmacología , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Descubrimiento de Drogas , Nifurtimox/farmacología , Nitroimidazoles/farmacología , Trypanosoma cruzi/efectos de los fármacos , Antiparasitarios/síntesis química , Antiparasitarios/química , Humanos , Nifurtimox/síntesis química , Nifurtimox/química , Nitroimidazoles/síntesis química , Nitroimidazoles/química , Pruebas de Sensibilidad ParasitariaRESUMEN
American Trypanosomiasis or Chagas disease is a prevalent, neglected and serious debilitating illness caused by the kinetoplastid protozoan parasite Trypanosoma cruzi. The current chemotherapy is limited only to nifurtimox and benznidazole, two drugs that have poor efficacy in the chronic phase and are rather toxic. In this scenario, more efficacious and safer drugs, preferentially acting through a different mechanism of action and directed against novel targets, are particularly welcome. Cruzipain, the main papain-like cysteine peptidase of T. cruzi, is an important virulence factor and a chemotherapeutic target with excellent pre-clinical validation evidence. Here, we present the identification of new Cruzipain inhibitory scaffolds within the GlaxoSmithKline HAT (Human African Trypanosomiasis) and Chagas chemical boxes, two collections grouping 404 non-cytotoxic compounds with high antiparasitic potency, drug-likeness, structural diversity and scientific novelty. We have adapted a continuous enzymatic assay to a medium-throughput format and carried out a primary screening of both collections, followed by construction and analysis of dose-response curves of the most promising hits. Using the identified compounds as a starting point a substructure directed search against CHEMBL Database revealed plausible common scaffolds while docking experiments predicted binding poses and specific interactions between Cruzipain and the novel inhibitors.
Asunto(s)
Antiprotozoarios/farmacología , Ensayos Analíticos de Alto Rendimiento/métodos , Kinetoplastida/efectos de los fármacos , Proteínas Protozoarias/antagonistas & inhibidores , Antiprotozoarios/química , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Cisteína Endopeptidasas/química , Cisteína Endopeptidasas/metabolismo , Interacciones Huésped-Parásitos/efectos de los fármacos , Humanos , Kinetoplastida/enzimología , Kinetoplastida/fisiología , Simulación del Acoplamiento Molecular , Estructura Molecular , Nifurtimox/química , Nifurtimox/farmacología , Nitroimidazoles/química , Nitroimidazoles/farmacología , Dominios Proteicos , Proteínas Protozoarias/química , Proteínas Protozoarias/metabolismo , Trypanosoma cruzi/efectos de los fármacos , Trypanosoma cruzi/enzimología , Trypanosoma cruzi/fisiologíaRESUMEN
BACKGROUND & OBJECTIVE: Chagas disease or American trypanosomiasis is a major parasitic disease in Latin America with restricted available treatment: nifurtimox and benznidazole. These two drugs are ineffective in the chronic phase of the disease; therefore, there is a need for the development of new, efficient and safe drugs for the treatment of this pathology. With this goal, one of the promising targets is trypanothione reductase (TR), a key enzyme in the metabolism of Trypanosoma cruzi. CONCLUSION: In this review, we analyse the importance of TR as a drug target, as well as the well-known and new inhibitors reported in the last decade as potential therapeutic agents for Chagas disease.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Sistemas de Liberación de Medicamentos , NADH NADPH Oxidorreductasas/metabolismo , Tripanocidas/química , Tripanocidas/uso terapéutico , Trypanosoma cruzi/enzimología , Animales , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Estructura Molecular , Nifurtimox/química , Nifurtimox/farmacología , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacosRESUMEN
Chagas disease or American trypanosomiasis is a neglected tropical disease caused by the parasite Trypanosoma cruzi. Although the number of infected individuals has decreased, about 6-7 million people are infected worldwide. The chemotherapy drugs currently used are limited to benznidazole and nifurtimox. They are effective in acute phase, congenital transmission and children with chronic infection; however, recent clinical trials have shown limitations in adults with chronic infection, presenting drawbacks during the treatment. Thus, there is an urgent need for new effective, safe and affordable drugs to fight against this complex disease. There were high expectations for azole derivatives as they appeared to be the most promising drugs for the treatment of Chagas disease during the last decade; however, the disappointing results obtained so far in clinical trials evidenced the lack of correlation between preclinical and clinical development. Therefore, the feedback obtained from these studies should define the starting point for addressing a roadmap for the drug discovery process in the fight against this disease. To tackle this challenge, it is important to keep in mind the drug target profile, already defined by panels of experts, and the coordinated work involving multi-disciplinary networks focusing not only on the discovery of new drugs but also on the standardization of the protocols that would allow acceleration in the Chagas disease drug discovery process.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Tripanocidas/uso terapéutico , Enfermedad de Chagas/diagnóstico , Enfermedad de Chagas/parasitología , Ensayos Clínicos como Asunto , Descubrimiento de Drogas , Humanos , Nifurtimox/química , Nifurtimox/farmacología , Nifurtimox/uso terapéutico , Nitroimidazoles/química , Nitroimidazoles/farmacología , Nitroimidazoles/uso terapéutico , ARN Protozoario/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Tripanocidas/química , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Trypanosoma cruzi/genética , Trypanosoma cruzi/patogenicidadRESUMEN
With the aim of improving the available drugs for the treatment of Chagas disease, individual enantiomers of nifurtimox were characterized. The results indicate that the enantiomers are equivalent in their in vitro activity against a panel of Trypanosoma cruzi strains; in vivo efficacy in a murine model of Chagas disease; in vitro toxicity and absorption, distribution, metabolism, and excretion characteristics; and in vivo pharmacokinetic properties. There is unlikely to be any therapeutic benefit of an individual nifurtimox enantiomer over the racemic mixture.
Asunto(s)
Nifurtimox/química , Nifurtimox/farmacocinética , Tripanocidas/química , Tripanocidas/farmacocinética , Trypanosoma cruzi/efectos de los fármacos , Animales , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Femenino , Humanos , Masculino , Ratones , Nifurtimox/uso terapéutico , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Tripanocidas/efectos adversos , Tripanocidas/uso terapéuticoRESUMEN
For years, Chagas disease treatment has been limited to only two drugs of highly questionable and controversial use (Nifurtimox(®) and Benznidazole(®)). In the search of effective drugs, many efforts have been made, but only a few structures have emerged as actual candidates. Heading into this, the multitarget-directed approach appears as the best choice. In this framework, indazoles were shown to be potent Trypanosoma cruzi growth inhibitors, being able to lead both the formation of reactive oxygen species and the inhibition of trypanothione reductase. Herein, we discuss the main structural factors that rule the anti-T. cruzi properties of indazoles, and how they would be involved in the biological properties as well as in the action mechanisms, attempting to make parallels between the old paradigms and current evidences in order to outline what could be the next steps to follow in regard to the future drug design for Chagas disease treatment.
Asunto(s)
Indazoles/química , Tripanocidas/química , Trypanosoma cruzi/metabolismo , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Diseño de Fármacos , Humanos , Indazoles/farmacología , Indazoles/uso terapéutico , NADH NADPH Oxidorreductasas/antagonistas & inhibidores , NADH NADPH Oxidorreductasas/metabolismo , Nifurtimox/química , Nifurtimox/farmacología , Nifurtimox/uso terapéutico , Nitroimidazoles/química , Nitroimidazoles/farmacología , Nitroimidazoles/uso terapéutico , Proteínas Protozoarias/antagonistas & inhibidores , Proteínas Protozoarias/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Tripanocidas/farmacología , Tripanocidas/uso terapéutico , Trypanosoma cruzi/efectos de los fármacos , Trypanosoma cruzi/enzimologíaRESUMEN
Here we report identification of new lead compounds based on quinoline and indenoquinolines with variable side chains as antiprotozoal agents. Quinolines 32, 36 and 37 (Table 1) and indenoquinoline derivatives 14 and 23 (Table 2) inhibit the in vitro growth of the Trypanosoma cruzi, Trypanosoma brucei, Trypanosoma brucei rhodesiense subspecies and Leishmania infantum with IC50=0.25 µM. These five compounds have superior activity to that of the front-line drugs such as benznidazole, nifurtimox and comparable to amphotericin B. Thus these compounds constitute new 'leads' for further structure-activity studies as potential active antiprotozoal agents.
Asunto(s)
Antiprotozoarios/síntesis química , Quinolinas/química , Anfotericina B/química , Anfotericina B/farmacología , Antiprotozoarios/química , Antiprotozoarios/farmacología , Línea Celular , Supervivencia Celular/efectos de los fármacos , Humanos , Leishmania infantum/efectos de los fármacos , Nifurtimox/química , Nifurtimox/farmacología , Nitroimidazoles/química , Nitroimidazoles/farmacología , Pruebas de Sensibilidad Parasitaria , Quinolinas/síntesis química , Quinolinas/farmacología , Relación Estructura-Actividad , Trypanosoma brucei brucei/efectos de los fármacos , Trypanosoma brucei rhodesiense/efectos de los fármacos , Trypanosoma cruzi/efectos de los fármacosRESUMEN
EVALUATION OF: Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286, 13088-13095 (2011). The prodrug nifurtimox has been one of the pharmacologic alternatives to treat Chagas disease and currently forms part of a combinational therapy to treat West African trypanosomiasis. Despite this, nifurtimox's mechanism of action is only partially understood and has been related to induction of oxidative stress in the target cell. An alternative mechanism involving reductive activation by a eukaryotic type I nitroreductase has been described. Bloodstream form Trypanosoma brucei overexpressing enzymes, proposed to metabolize nifurtimox, were generated and only cells with elevated levels of the nitroreductase displayed altered susceptibility to the drug, implying that it has a key role in drug action. Reduction of nifurtimox by trypanosomal type I nitroreductases was shown to be insensitive to oxygen and yielded a product characterized by liquid chromatography/mass spectrometry as an unsaturated open chain nitrile. This nitrile inhibited both parasite and mammalian cell growth at equivalent concentrations, in marked contrast to the parental prodrug. These studies indicated that nifurtimox selectivity against T. brucei could be the result of the expression of a parasite-encoded type I nitroreductase.
Asunto(s)
Antiprotozoarios/farmacología , Nifurtimox/farmacología , Profármacos/farmacología , Antiprotozoarios/química , Humanos , Leishmania/efectos de los fármacos , Modelos Moleculares , Estructura Molecular , Nifurtimox/química , Profármacos/química , Trypanosoma brucei brucei/efectos de los fármacosRESUMEN
In a continuing effort to identify new active compounds for combating Chagas disease and other neglected diseases, our research group synthesized and evaluated 23 3-arylquinoxaline-2-carbonitrile di-N-oxides against Trypanosoma cruzi. Five of them presented IC(50) values of the same magnitude as the standard drug Nifurtimox, making them valid as new lead compounds. The optimized molecular structures of 23 derivatives represented by 1497 types of DRAGON descriptors were subjected to linear regression analysis, and the derived QSAR was shown to be predictive. In this way, we achieved a rational guide for the proposal of new candidate structures whose activities still remain unknown.
Asunto(s)
Óxidos/química , Quinoxalinas/química , Tripanocidas/química , Trypanosoma cruzi/efectos de los fármacos , Nifurtimox/química , Nifurtimox/farmacología , Relación Estructura-Actividad Cuantitativa , Quinoxalinas/farmacología , Tripanocidas/farmacologíaRESUMEN
Chagas disease is caused by the trypanosomatid parasite Trypanosoma cruzi and threatens millions of lives in South America. As other neglected diseases there is almost no research and development effort by the pharmaceutical industry and the treatment relies on two drugs, Nifurtimox and Benznidazole, discovered empirically more than three decades ago. Nifurtimox, a nitrofurane derivative, is believed to exert its biological activity through the bioreduction of the nitro-group to a nitro-anion radical which undergoes redox-cycling with molecular oxygen. This hypothesis is generally accepted, although arguments against it have been presented. In the present work we studied the ability of Nifurtimox and five N-oxide-containing heterocycles to induce oxidative stress in T. cruzi. N-Oxide-containing heterocycles represent a promising group of new trypanosomicidal agents and their mode of action is not completely elucidated. The results here obtained argue against the oxidative stress hypothesis almost for all the studied compounds, including Nifurtimox. A significant reduction in the level of parasitic low-molecular-weight thiols was observed after Nifurtimox treatment; however, it was not linked to the production of reactive oxidant species. Besides, redox-cycling is only observed at high Nifurtimox concentrations (>400microM), two orders of magnitude higher than the concentration required for anti-proliferative activity (5microM). Our results indicate that an increase in oxidative stress is not the main mechanism of action of Nifurtimox. Among the studied N-oxide-containing heterocycles, benzofuroxan derivatives strongly inhibited parasite dehydrogenase activity and affected mitochondrial membrane potential. The indazole derivative raised intracellular oxidants production, but it was the least effective as anti-T. cruzi.
Asunto(s)
Óxidos N-Cíclicos/farmacología , Nifurtimox/farmacología , Estrés Oxidativo/efectos de los fármacos , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Benzoxazoles/farmacología , Células Cultivadas , Óxidos N-Cíclicos/química , Potenciales de la Membrana/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Estructura Molecular , Nifurtimox/química , Oxidación-Reducción/efectos de los fármacos , Oxidorreductasas/efectos de los fármacos , Oxidorreductasas/metabolismo , Oxígeno/metabolismo , Tripanocidas/química , Trypanosoma cruzi/crecimiento & desarrollo , Trypanosoma cruzi/metabolismoRESUMEN
Ten 5-nitro-2-furyl derivatives, with good to excellent in vitro anti-Trypanosoma cruzi activity, and nifurtimox were tested oral and intraperitoneally on healthy animals for its acute toxicity on murine models. According to animals' survival percentage, organ histological results, biochemical and haematological findings, three new derivatives, with toxicity like nifurtimox, were selected to test in vivo as antichagasic agents. Clearly, dependences between chemical structure and both acute toxicity and in vivo anti-T. cruzi activity were observed. 4-Hexyl-1-[3-(5-nitro-2-furyl)-2-propenylidene]semicarbazide displayed good profile as anti-T. cruzi agent and better acute toxicity profile than nifurtimox.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Nifurtimox/química , Nifurtimox/uso terapéutico , Nitrofuranos/química , Nitrofuranos/uso terapéutico , Tripanocidas/química , Tripanocidas/uso terapéutico , Animales , Enfermedad de Chagas/patología , Femenino , Ratones , Nifurtimox/toxicidad , Nitrofuranos/toxicidad , Relación Estructura-Actividad , Tripanocidas/toxicidad , Trypanosoma cruzi/efectos de los fármacosRESUMEN
Electron spin resonance (ESR) spectra of radicals obtained from two analogues of the antiprotozoal drug nifurtimox by electrolytic and Trypanosoma cruzi reduction were analyzed. The electrochemistry of these compounds was studied using cyclic voltammetry. STO 3-21G ab initio and INDO molecular orbital calculations were performed to obtain the optimized geometries and spin distribution, respectively. The antioxidant effect of glutathione on the nitroheterocycle radical was evaluated. DMPO spin trapping was used to investigate the possible formation of free radicals in the trypanosome microsomal system. Nitro1 and Nitro2 nitrofuran analogues showed better antiparasitic activity than nifurtimox. Nitro2 produced oxygen redox cycling in T. cruzi epimastigotes. The ESR signal intensities were consistent with the trapping of either the hydroxyl radical or the Nitro2 analogue radicals. These results are in agreement with the biological observation that Nitro2 showed anti-Chagas activity by an oxidative stress mechanism.
Asunto(s)
Antiprotozoarios/química , Nifurtimox/química , Nitrofuranos/química , Trypanosoma cruzi/efectos de los fármacos , Trypanosoma cruzi/fisiología , Animales , Antiprotozoarios/farmacología , Electroquímica , Espectroscopía de Resonancia por Spin del Electrón , Radicales Libres/análisis , Nifurtimox/farmacología , Nitrofuranos/farmacología , Detección de SpinRESUMEN
In a search for antichagasic drugs, 14 new 4-(nitroarylidene)-1,2,6-thiadiazin-3,5-dione 1,1-dioxide derivatives were synthesized and tested in vitro against the epimastigote form of Trypanosoma cruzi and some of them showed important antiprotozoan activity. Attempts to synthesize new 4-(nitroarylidene)-3,5-diamino-1,2,6-thiadiazine 1,1-dioxides were unsuccessful. The antichagasic properties of nitroarylidene-malononitrile and nitroarylidene-cyanoacetamide derivatives, thus obtained, were also tested. The cytotoxic properties against Vero cells of compounds which showed remarkable in vitro antichagasic activity were evaluated. All compounds tested exhibited high toxicity percentages at 100 micrograms/ml. However, compound 3c showed in vitro antichagasic and cytotoxic properties such as nifurtimox at the dose of 10 micrograms/ml.